---
title: "Immutep Reaches 50% Enrolment in Global Phase III TACTI-004 Lung Cancer Trial"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/275444849.md"
datetime: "2026-02-10T11:03:05.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/275444849.md)
  - [en](https://longbridge.com/en/news/275444849.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/275444849.md)
---

> 支持的语言: [English](https://longbridge.com/en/news/275444849.md) | [繁體中文](https://longbridge.com/zh-HK/news/275444849.md)


# Immutep Reaches 50% Enrolment in Global Phase III TACTI-004 Lung Cancer Trial

Immutep Ltd. has announced that it has reached 50% enrolment in its global TACTI-004 (KEYNOTE-F91) Phase III clinical trial. The study is evaluating eftilagimod alfa (efti) in combination with MSD’s KEYTRUDA® (pembrolizumab) and chemotherapy as a first-line therapy for advanced or metastatic non-small cell lung cancer (1L NSCLC). As of now, 378 patients have been enrolled across more than 140 clinical sites in 27 countries. The company stated that the futility analysis is scheduled for the first quarter of 2026, with full patient enrolment expected to be completed in the third quarter of 2026. No study results have been presented yet. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immutep Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-043193), on February 10, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### 相关股票

- [SPDR S&P Biotech (XBI.US)](https://longbridge.com/zh-CN/quote/XBI.US.md)
- [ALPS Medical Breakthrough (SBIO.US)](https://longbridge.com/zh-CN/quote/SBIO.US.md)
- [Immutep (IMMP.US)](https://longbridge.com/zh-CN/quote/IMMP.US.md)
- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/zh-CN/quote/BBH.US.md)
- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/zh-CN/quote/IBB.US.md)
- [VG Health (VHT.US)](https://longbridge.com/zh-CN/quote/VHT.US.md)
- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/zh-CN/quote/PBE.US.md)
- [Health Care Select Sector SPDR (XLV.US)](https://longbridge.com/zh-CN/quote/XLV.US.md)
- [Invesco Nasdaq Biotechnology ETF (IBBQ.US)](https://longbridge.com/zh-CN/quote/IBBQ.US.md)
- [Ark Genomic Revolution ETF (ARKG.US)](https://longbridge.com/zh-CN/quote/ARKG.US.md)
- [iShares Global Healthcare (IXJ.US)](https://longbridge.com/zh-CN/quote/IXJ.US.md)
- [Immutep Ltd (IMM.AU)](https://longbridge.com/zh-CN/quote/IMM.AU.md)
- [BlackRock, Inc. (IXJ.AU)](https://longbridge.com/zh-CN/quote/IXJ.AU.md)
- [First Trust NYSE Arca Biotech Index Fd (FBT.US)](https://longbridge.com/zh-CN/quote/FBT.US.md)
- [iShares US Pharma (IHE.US)](https://longbridge.com/zh-CN/quote/IHE.US.md)

## 相关资讯与研究

- [Immutep halts late-stage trial for lead asset after efficacy analysis](https://longbridge.com/zh-CN/news/279032924.md)
- [Immutep Discontinues Phase III Trial Of Eftilagimod Alfa In First-Line NSCLC; Stock Drops](https://longbridge.com/zh-CN/news/279000682.md)
- [Clene 2025 net loss narrows as expenses fall](https://longbridge.com/zh-CN/news/278880252.md)
- [Oragenics receives HREC approval, begins Phase IIa ONP-002 site initiation in Australia](https://longbridge.com/zh-CN/news/278776483.md)
- [Incannex Healthcare Prices $10 Mln Potential Offering Of Shares And Warrants; Stock Down](https://longbridge.com/zh-CN/news/278896600.md)